NCT01001013View on ClinicalTrials.gov

Pharmacokinetic Drug Interaction Between LC15-0444 and Pioglitazone After Oral Administration in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

June 30, 2009

Study Completion Date

December 31, 2009

Conditions

Healthy

Interventions

DRUG

LC15-0444, Pioglitazone

LC15-0444 200 mg (100 mg x 2) qd (12 days once daily) Pioglitazone 30 mg (15 mg x 2) qd (12 days once daily) LC15-0444 200 mg (100 mg x 2) qd + pioglitazone 30 mg (15 mg x 2) qd (12 days once daily)

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul